News | May 14, 2026
Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
